COMPANY RESEARCHSimnova holds Greater China development and commercialization rights for partnered Orna in vivo cell therapies. The January 2025 expansion adds BCMA to the circular RNA partnership. Territorial participation is retained without counting the partnered programs as unrelated inventions; current clinical stage was not verified.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Simnova holds Greater China development and commercialization rights for partnered Orna in vivo cell therapies. The January 2025 expansion adds BCMA to the circular RNA partnership. Territorial participation is retained without counting the partnered programs as unrelated inventions; current clinical stage was not verified.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Orna partnered panCAR | CD19; BCMA · See program source; distinguish indications | Not verified | No human CAR-T evidence verified in this review. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature study delivered guide RNA and base-editor mRNA in GalNAc lipid nanoparticles to inactivate liver ANGPTL3. Nonhuman primates showed mean ANGPTL3 protein reductions exceeding 90%, with durability assessed through three years after one dose. Lipid reductions were observed in animal models. Human liver-cell testing assessed selected off-target sites; the paper does not report human clinical efficacy.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.